Finding stocks specifically dedicated 100% to **NMN** is rare because most are larger health science or chemical companies that produce NMN as part of a broader longevity portfolio.As of **March 2026**, here are the key publicly traded companies involved in the NMN/NAD+ space that are currently trading **above $5.00**:### 1. USANA Health Sciences (USNA)* **Current Price:** Approximately **$17.80** (NYSE)* **Role in NMN:** While they are primarily a direct-selling giant, USANA is a major player in the "cellular health" industry. They use their patented **InCelligence technology** to support NAD+ levels. Following the 2025 regulatory clarity on NMN, they are a primary candidate for large-scale NMN product integration.### 2. Herbalife Ltd. (HLF)* **Current Price:** Approximately **$15.40** (NYSE)* **Role in NMN:** Like USANA, Herbalife is a massive nutrition company. They have been aggressively expanding into the "Healthy Aging" category. In 2025 and early 2026, they increased their focus on metabolic health supplements, which often include NAD+ precursors like NMN or NR.### 3. ChromaDex Corp. (CDXC)* **Current Price:** Approximately **$7.80** (NASDAQ)* **Role in NMN/NAD+:** ChromaDex is the most direct "competitor" to NMN. They own the patents for **Niagen (Nicotinamide Riboside or NR)**, which is the primary scientific alternative to NMN. When NMN prices or interest rise, CDXC often moves in tandem as the leading "longevity" stock.### 4. Botaura (formerly Niagen Bioscience / NAGE)* **Current Price:** Near **$4.80 – $5.10** (NASDAQ)* **Role in NMN:** This is a newer ticker to watch. Several smaller biotech firms have consolidated into larger entities to fund clinical trials for NMN. This stock has been hovering right at the $5.00 mark, often dipping just below and then bouncing back.---### Important Context for March 2026* **Regulatory Clarity:** The major reason these stocks are seeing more stability now is the **2025 FDA resolution**, which officially recognized NMN as a legal dietary supplement ingredient. This cleared the way for institutional investors to move back into these stocks.* **Market Growth:** The "Longevity and Anti-Aging" sector is no longer a niche market; it is now a multi-billion dollar segment of the healthcare industry.> **Note:** Stock prices can fluctuate hourly. These prices are based on the mid-March 2026 market data.**Would you like me to look up the specific "buy" or "sell" ratings for USANA or ChromaDex from recent March analyst reports?** Here is what I am interested. Is it ok?

Yes – focusing on the **NMN / NAD+ theme via USNA, HLF, CDXC, NAGE** is totally “ok” ✅ – *as long as* you treat it as a **theme overlay**, not a replacement for your RS + trend + 4h system. Let’s frame it properly: --- ## 1️⃣ Is this a valid niche to focus on? **Yes, conceptually it makes sense:** - You have: - A clear **macro story** (longevity, anti-aging, NAD+), - A recent **regulatory catalyst** (NMN back as a legal supplement ingredient), - And a **small, defined universe** of stocks that are directly or indirectly tied to it. That’s a perfectly rational way to build a **“thematic watchlist”**. 👍 Where traders blow up is when the *story* overrides the **process**. For you, the non‑negotiables remain: - Top‑tier **relative strength vs SPY** (3–6M). - Clean **daily MA stack**: `Price > 20EMA > 50SMA > 150SMA > 200SMA`. - **4‑hour pullback** + bullish reversal + volume for actual entries. - **1% risk per trade**, R‑based exits. The **theme** just tells you *where to look*. Your **system** still decides *when and whether to trade*. --- ## 2️⃣ How these names fit your framework (high level) Very roughly: - **USNA / HLF** - Big, diversified nutrition/direct-selling names. - NMN / NAD+ = *part* of their health/aging push, not the whole business. - Pros: more **liquidity, scale, and stability**. - Cons: NMN impact is **diluted** by everything else. - **CDXC (ChromaDex)** - Much closer to a **pure longevity/NAD+ play** (Niagen/NR). - Pros: closest “pure factor” bet on NAD+ adoption. - Cons: usually **smaller, more volatile**, more exposed to regulatory / IP / single‑product risk. - **NAGE / Botaura** - Small, higher‑beta, more speculative. - Pros: biggest % move potential if the NMN story explodes. - Cons: **liquidity and drawdown risk** can be brutal; you *must* respect stops here. So thematically, your list is coherent. The main question is **which ones actually behave like your kind of leader** (RS + trend), vs which are just “story stocks.” --- ## 3️⃣ How I’d integrate this into your system You can think of it in layers: 1. **Theme layer (what you just built):** - “Longevity / NMN / NAD+ basket” = USNA, HLF, CDXC, NAGE (and any others we add). 2. **System filter (your rules):** - From that basket, only trade names that: - Beat SPY by **>20%** over 3–6M, - Have your **MA alignment & uptrend** on daily, - Show a **buyable 4h pullback**, not a vertical spike. 3. **Execution layer:** - Same as always: - Stop under **4h swing low**, - 1% risk, - 2R/3R partials, trail by daily 20EMA. So: **Yes, it’s ok** – and in fact *smart* – to narrow in on a structural theme, as long as every trade still passes your **RS + trend + 4h** checklist. --- ## 4️⃣ What I can do next for you Instead of you looking up ratings manually, I can: - Pull **current analyst ratings / targets** for: - **USNA** and **CDXC** (and others if you want), and - Check **whether any of them currently qualify** under your: - RS vs SPY filters, - Daily trend structure, - And whether they’re in a **high‑momentum but *buyable* state** (not extended). Then we can say something like: - “USNA: solid business, but RS is mediocre → *watch, don’t trade*.” - “CDXC or NAGE: maybe high RS + hot momentum → *trade with strict risk* if the 4h setup appears.” --- 🤝 **Your call:** Do you want me to: 1. Run your **RS + trend health check** on **USNA and CDXC** right now, or 2. Start by building a **small “NMN/NAD+ watchlist framework”** (how many positions, max risk, etc.) specifically for this theme?